The efficacy of the drug was proven in several types of cancer and, consequently, atezolizumab has indications for unresectable advanced or recurrent NSCLC, adjuvant therapy for PD-L1-positive NSCLC, advanced small cell lung cancer (SCLC), unresectable hepatocellular carcinoma (HCC), and PD-L1-positive unresectable or recurrent triple-negative breast cancer. Here, CD274 is linked to small cell lung carcinoma.